NATCO Pharma to Launch Generic Semaglutide in India March 21 at ₹1,290

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
NATCO Pharma to Launch Generic Semaglutide in India March 21 at ₹1,290
Overview

NATCO Pharma will launch its generic Semaglutide injection in India on March 21, 2026, offering significant cost savings for type 2 diabetes and obesity treatments. The multi-dose vials will start at ₹1,290, positioning it as the most affordable GLP-1 therapy in the market and improving patient access.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

CDSCO Approves Generic Semaglutide for NATCO Pharma

NATCO Pharma received approval from India's Central Drugs Standard Control Organisation (CDSCO) in February 2026 to produce and sell its generic Semaglutide. The approval, granted after clinical studies confirmed bioequivalence, covers both multi-dose vials and pen devices. This clearance allows NATCO to introduce what is expected to be the first affordable GLP-1 therapy in the Indian market.

NATCO Pharma's Pricing Strategy for Semaglutide Launch

Under the brand names SEMANAT™ and SEMAFULL™, the drug is designed to make advanced treatments for diabetes and obesity more accessible. NATCO Pharma has set the monthly price for multi-dose vials at ₹1,290 for 2mg/1.5ml and 4mg/3ml strengths, and ₹1,750 for the 8mg/3ml strength. A pen device version, expected in April 2026, will be priced between ₹4,000 and ₹4,500 monthly. This pricing makes NATCO's Semaglutide approximately 70% less expensive than existing pen devices and 90% cheaper than originator brands.

NATCO Pharma Stock Reacts Positively to Launch News

The announcement coincided with a positive market reaction for NATCO Pharma, with its stock surging 3.06% on March 20, 2026, trading at ₹966.80. Year-to-date, the shares have climbed 8.26%, and its one-year performance is 16.40%. This anticipated market disruption and improved patient access are expected to drive future growth for the company.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.